Krishna G - Search Results

1

Evaluation of the Potential for QTc Prolongation With Repeated Oral Doses of Fedratinib in Patients With Advanced Solid Tumors.

Ogasawara K, Xu C, Yin J, Darpo B, Carayannopoulos L, Xue H, Palmisano M, Krishna G. Ogasawara K, et al. Among authors: krishna g. Clin Pharmacol Drug Dev. 2021 Apr;10(4):366-375. doi: 10.1002/cpdd.850. Epub 2020 Jul 16. Clin Pharmacol Drug Dev. 2021. PMID: 32673446 Clinical Trial.

2

Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia.

Ogasawara K, Zhou S, Krishna G, Palmisano M, Li Y. Ogasawara K, et al. Among authors: krishna g. Cancer Chemother Pharmacol. 2019 Oct;84(4):891-898. doi: 10.1007/s00280-019-03929-9. Epub 2019 Aug 23. Cancer Chemother Pharmacol. 2019. PMID: 31444617 Free PMC article. Clinical Trial.

3

Effects of repeated oral doses of ketoconazole on a sequential ascending single oral dose of fedratinib in healthy subjects.

Ogasawara K, Xu C, Kanamaluru V, Palmisano M, Krishna G. Ogasawara K, et al. Among authors: krishna g. Cancer Chemother Pharmacol. 2020 May;85(5):899-906. doi: 10.1007/s00280-020-04067-3. Epub 2020 Apr 4. Cancer Chemother Pharmacol. 2020. PMID: 32248324

4

A phase I study of the effect of repeated oral doses of pantoprazole on the pharmacokinetics of a single dose of fedratinib in healthy male subjects.

Ogasawara K, Vince B, Xu C, Zhang M, Palmisano M, Krishna G. Ogasawara K, et al. Among authors: krishna g. Cancer Chemother Pharmacol. 2020 May;85(5):995-1001. doi: 10.1007/s00280-020-04074-4. Epub 2020 Apr 22. Cancer Chemother Pharmacol. 2020. PMID: 32318809 Clinical Trial.

5

Pharmacokinetics and tolerability of fedratinib, an oral, selective Janus kinase 2 inhibitor, in subjects with renal or hepatic impairment.

Ogasawara K, Smith WB, Xu C, Yin J, Palmisano M, Krishna G. Ogasawara K, et al. Among authors: krishna g. Cancer Chemother Pharmacol. 2020 Jun;85(6):1109-1117. doi: 10.1007/s00280-020-04084-2. Epub 2020 May 24. Cancer Chemother Pharmacol. 2020. PMID: 32449142 Clinical Trial.

6

Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach.

Ogasawara K, LoRusso PM, Olszanski AJ, Rixe O, Xu C, Yin J, Palmisano M, Krishna G. Ogasawara K, et al. Among authors: krishna g. Cancer Chemother Pharmacol. 2020 Jul;86(1):87-95. doi: 10.1007/s00280-020-04102-3. Epub 2020 Jun 14. Cancer Chemother Pharmacol. 2020. PMID: 32537715 Clinical Trial.

7

Excretion balance and pharmacokinetics following a single oral dose of [¹⁴C]-fedratinib in healthy subjects.

Ogasawara K, Xu C, Kanamaluru V, Siebers N, Surapaneni S, Ridoux L, Palmisano M, Krishna G. Ogasawara K, et al. Among authors: krishna g. Cancer Chemother Pharmacol. 2020 Aug;86(2):307-314. doi: 10.1007/s00280-020-04121-0. Epub 2020 Aug 3. Cancer Chemother Pharmacol. 2020. PMID: 32748109

8

Physiologically based pharmacokinetic modeling to assess metabolic drug-drug interaction risks and inform the drug label for fedratinib.

Wu F, Krishna G, Surapaneni S. Wu F, et al. Among authors: krishna g. Cancer Chemother Pharmacol. 2020 Oct;86(4):461-473. doi: 10.1007/s00280-020-04131-y. Epub 2020 Sep 4. Cancer Chemother Pharmacol. 2020. PMID: 32886148 Free PMC article.

9

Effects of strong and moderate CYP3A4 inducers on the pharmacokinetics of fedratinib in healthy adult participants.

Ogasawara K, Kam J, Thomas M, Liu L, Liu M, Xue Y, Surapaneni S, Carayannopoulos LN, Zhou S, Palmisano M, Krishna G. Ogasawara K, et al. Among authors: krishna g. Cancer Chemother Pharmacol. 2021 Sep;88(3):369-377. doi: 10.1007/s00280-021-04292-4. Epub 2021 May 21. Cancer Chemother Pharmacol. 2021. PMID: 34019108 Clinical Trial.

10

Impact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approach.

Ogasawara K, Wood-Horrall RN, Thomas M, Thomas M, Liu L, Liu M, Xue Y, Surapaneni S, Carayannopoulos LN, Zhou S, Palmisano M, Krishna G. Ogasawara K, et al. Among authors: krishna g. Cancer Chemother Pharmacol. 2021 Dec;88(6):941-952. doi: 10.1007/s00280-021-04346-7. Epub 2021 Sep 3. Cancer Chemother Pharmacol. 2021. PMID: 34477937

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

653 results

Search Page

Filters